December 4, 2012
Corium International and Capital Royalty Close Financing Transactions
Menlo Park, CA, December 4, 2012 — Corium International, Inc. (“Corium”) and Capital Royalty Partners II, L.P. (“Capital Royalty”) announced that they have closed a term loan facility for up to $35 million of capital. Corium is a privately-held transdermal drug delivery company with a strong track record of successful development and manufacture of advanced pharmaceutical products. Corium intends to use the proceeds to refinance its outstanding debt, support corporate growth initiatives, and execute on its strategic plan.